case_images: PMC9797958_01
case_images: Timeline of the disease course.
case_images: fonc-12-1089108-g001.jpg
case_images: PMC9797958_01_fonc-12-1089108-g001.jpg
case_images: f1
case_images: A last-ditch attempt was decided by initiating a TKI treatment with osimertinib 80 mg per day, first dose received on June 28 ( Figure 1 ). A second control was performed on July 12, finding 6,377 copies/mL for EGFR DEL19 and a possible EGFR T790M resistance mutation at 4.0 copies/mL ( Figure 1 ). CT-scan performed shows a partial morphological response according to RECIST1.1 criteria ( Figure 2 ). Control of ctDNA rate revealed a residual value for the EGFR DEL19 activating mutation (40.0 copies/mL) and the disappearance of the EGFR T790M mutation ( Figure 1 ).
case_images: Comparison of CT scans before (June 7, A, B) and with osimertinib treatment (August 29, C, D). Size reduction of primary tumor (cyan) and target hepatic metastasis (red). Disparition of pleural effusion (green arrows).
case_images: fonc-12-1089108-g002.jpg
case_images: PMC9797958_01_fonc-12-1089108-g002.jpg
case_images: f2
case_images: CT-scan performed shows a partial morphological response according to RECIST1.1 criteria ( Figure 2 ). Control of ctDNA rate revealed a residual value for the EGFR DEL19 activating mutation (40.0 copies/mL) and the disappearance of the EGFR T790M mutation ( Figure 1 ).